Search Results
Jun 30, 2026, 13:00 ET Inductive Bio joins Anthropic's Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through Claude
are not retained or used to train Inductive's models.Scientists and teams interested in Inductive Bio's full suite of ADMET and pharmacokinetic (PK) models - as well as models fine-tuned to their own chemical space - are encouraged to
More news about: Inductive Bio, Inc.
Jun 30, 2026, 08:53 ET Ivybrook Academy Launches $5,000 Franchise Reduction for Educators Pursuing Ownership*
franchise entity) must provide verifiable proof of current or past employment as a certified teacher, school administrator, or educator at an accredited PK-12 or postsecondary institution. This discount is non-transferable, cannot be combined with any other promotional offers or incentives (such as veteran
More news about: Ivybrook Academy
Jun 26, 2026, 10:30 ET Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted
therapeutic benefits and bleeding risks of antiplatelet medications.A series of completed clinical studies, including Phase I, Phase II, China-US PK/PD bridging study and Phase III trials, have fully validated the clinical efficacy and safety of Sumecigrel Capsule. It boasts multiple advantages
More news about: Jiangsu Vcare Pharmatech Co., Ltd.
Jun 26, 2026, 09:00 ET Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
presentation: Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off
More news about: Novo Nordisk
Jun 26, 2026, 09:00 ET Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
presentation: Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off
More news about: Novo Nordisk
Jun 24, 2026, 14:40 ET GSMA MWC26上海でヒューマノイドロボットのPK戦を観戦
View original content to download multimedia:https://www.prnewswire.com/jp/news-releases/gsma-mwc26pk-302809732.htmlSOURCE GSMA
More news about: GSMA
Jun 24, 2026, 09:00 ET Teaching Strategies Named Finalist for Three 2026 CODiE Awards
the full education continuum." Teaching Strategies' solutions are being recognized in the following categories:Best PK/Early Childhood Learning Solution: The research-based and evidence-based curriculum for 3- and 4-year-olds,
More news about: Teaching Strategies
Jun 24, 2026, 08:36 ET HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programsBOSTON and SUZHOU, China, June
More news about: HKeyBio
Jun 24, 2026, 08:15 ET The Results Are In: IXL Helps Prevent Summer Learning Loss
IXLCurrently used by 18 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a next-generation assessment suite. Available in more than 120 languages, IXL's end-to-end
More news about: IXL Learning
Jun 24, 2026, 07:05 ET Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
of obesity and overweight later this year.Based on VK2735's promising efficacy and differentiated pharmacokinetic (PK) profile, the company is evaluating a range of novel dosing regimens for both the induction and the long-term maintenance of weight loss. In October
More news about: Viking Therapeutics, Inc.
Jun 23, 2026, 07:04 ET Celebrate America's 250th Birthday with Even More Affordable(SM) Fourth of July Deals from Natural Grocers®
bring bold taste and just the right amount of heat to your backyard barbecue.Cool off with Yachak Organic Yerba Mate Energy Drinks ($18.49/12 pk or $1.79 each). Crafted with organic yerba mate, a natural source of caffeine, these refreshing drinks are the perfect companion for long summer days
More news about: Natural Grocers by Vitamin Cottage, Inc.
Jun 23, 2026, 03:01 ET PointsKash Announces Strategic Partnership with BitCorp Inc. to Accelerate Nationwide Merchant Expansion Across More Than 100,000 Potential Locations
national growth strategy and is expected to significantly expand the Company's merchant distribution footprint for its KashPoint™ financial services kiosks, PK Pay™ mobile application, rewards monetization platform, and future financial center initiatives.As part of the partnership, BitCorp is expected
More news about: PointsKash Inc.
Jun 18, 2026, 11:00 ET Major Milestone: IXL Learners Answer 200 Billion Questions
Currently used by 18 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 120 languages, IXL's end-to-end
More news about: IXL Learning
Jun 17, 2026, 12:21 ET North Carolina teachers named 2026 CERTIFIED Educators of the Year
Pearson Empowers Teachers with "Foundations of AI for PK-12 Educators" Course
More news about: Pearson
Jun 17, 2026, 09:00 ET Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
trial, including both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered ISM8969 in healthy participants and in obese adult participants at risk of cardiovascular disease.
More news about: Insilico Medicine
Jun 16, 2026, 08:00 ET ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
potent, selective, CNS-penetrant MAP4K inhibitor—in participants with ALS. PRO-101 was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of prosetin. Interim data from the multiple ascending dose (MAD) portion of PRO-101, which includes 41 ALS participants across
More news about: ProJenX
Jun 15, 2026, 08:11 ET Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
focused on the treatment of EGFR inhibitor-associated skin toxicities. The pharmacokinetic (PK) portion of the HT-001 Phase 2 clinical program has been completed, and the Company is currently awaiting finalized PK results. Additional portions of the Phase 2 program remain ongoing.As
More news about: Rocket One Inc.
Jun 15, 2026, 07:00 ET Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
following multiple doses compared to baseline.Pharmacokinetics (PK): BBT002 exhibited prolonged PK with a half-life of approximately 29.4 days at or above target exposure, consistent with the PK profile observed in the single ascending dose (SAD) cohorts, supporting the potential
More news about: Bambusa Therapeutics, Inc.
Jun 11, 2026, 12:23 ET FGM Architects Named to Crain's Chicago Business Fast 50 List for 2026
commitment to delivering impactful design solutions that strengthen communities. The firm's continued success reflects increasing demand for its expertise in PK-12 and higher education, public safety, municipal, recreation, faith-based and civic environments."We are honored to be recognized by Crain's
More news about: FGM Architects
Jun 11, 2026, 02:23 ET Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO
COVID-19, whose efficacy has been proven in human trials, or against dengue virus, currently in trials.Pharmacokinetic (PK) validity: On the basis of the blood drug concentrations in the body confirmed through the trial in 300 COVID-19 patients, the Ebola virus, too,
More news about: Hyundai Bioscience
Jun 10, 2026, 09:16 ET HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices
development."The program offers flexible service modules covering pharmacokinetic profiling, target engagement assessment, receptor occupancy analysis, PK/PD correlation evaluation and early developability confirmation. It is particularly applicable to siRNA and biologics targeting immune pathways such
More news about: HKeyBio
Jun 10, 2026, 05:00 ET Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
improvements in PK parameters including AUC, and hematologic safety markers including absolute neutrophil count. These findings suggest that ALT-B4-enabled subcutaneous formulations go beyond improving dosing convenience, and may serve as a starting point for a paradigm shift in optimizing the PK and safety
More news about: Alteogen Inc.
Jun 10, 2026, 02:22 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:19 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production
More news about: H. Lundbeck A/S
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
tolerability of ATG-201 monotherapy and to determine its recommended Phase II dose (RP2D). Secondary objectives include evaluating the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, immunogenicity, preliminary efficacy of ATG-201.Professor Zhanguo Li stated, "It is a great honor to
More news about: Antengene Corporation Limited